TABLE IV.
Pt id | Primary tumour size (cm) | Distant metastatic sites (clinical) | TNM stagea | Immunohistochemistry |
---|---|---|---|---|
1 | 4 | Lung, vertebral | pT3a (perirenal and hilar fat), N1, M1 | Not available |
2 | 7 | Bilateral adrenal | pT4 (splenic invasion), N1, M1 | Positive: CK19, HMW-CK, EMA, vimentin, CK7 Negative: CD10, p63 |
3 | 12 | Lung, bilateral | cT3b (ivc extension) possible cT4, N1, M1 | Positive: CK7, CK5/6, p63 Focally positive: MOC31, vimentin, CD10 Negative: CD20 |
4 | 11 | Adrenal, liver, lung, vertebral | cT4, N1, M1 | Positive: AE1/AE3, CAM5.2, 34BE12, CK7, CK10 Negative: CK20, PSA, PAP, EMA, vimentin, TTF-1 |
5 | 4 | None | pT1, N1, M0 | Not available |
6 | 5 | Liver | pT3, N0, M1, R1 mixed Fuhrman 3 ccrcc and cdc | Positive: CK7 |
According to the AJCC Cancer Staging Manual14.
Pt = patient; ivc = inferior vena cava; ccrcc = clear cell renal cell carcinoma; cdc = collecting duct carcinoma.